Status checked July 24, 2026. Review retatrutide’s U.S. investigational status, RUO limits, compounding restrictions, marketing, import, and research rules.
Retatrutide U.S. Legal Status for Research
read more...
Retatrutide
What Is Retatrutide (LY3437943)? Research Overview
Retatrutide, or LY3437943, is an investigational GIPR/GLP-1R/GCGR triple agonist. This research-only overview explains its nomenclature, receptor profile, evidence timeline, current status, and analytical-documentation requirements.
Retatrutide Research Applications
A source-led overview of retatrutide receptor pharmacology, phase 2 evidence, ongoing clinical research, and laboratory study considerations.
Retatrutide vs GLP-1 and GLP-1/GIP Dual Agonists
Compare retatrutide with GLP-1 receptor and GIP/GLP-1 dual agonists, including receptor targets, study controls, and analytical-quality requirements.
How Researchers Are Studying Retatrutide: Vials, Pens, and Bulk Formats
Research teams choose a Retatrutide format around the work that must be documented, not around a packaging shortcut. A vial, cartridge, or larger research format may carry the same compound name, but the container does not prove identity, measured content,...
Retatrutide Triple Agonist in Metabolic Research
A receptor-biology guide to retatrutide’s GLP-1, GIP, and glucagon receptor agonism, with controls for interpretable laboratory studies.